Eric K. Singhi, MD

In this segment, Dr. Devarakonda asks Dr. Rotow to address the role of dose interruptions and reductions in managing treatment related toxicities in EGFR mutated metastatic non-small cell lung cancer.

In this segment, the discussion shifts to a 70 year old patient with EGFR mutated metastatic non-small cell lung cancer who is experiencing dermatologic toxicity several months into first line EGFR targeted therapy.

In this segment, the panel further examines the case of a patient with EGFR mutated metastatic non-small cell lung cancer and asymptomatic brain metastases.

In this case based segment, Dr. Devarakonda introduces a newly diagnosed 62 year old patient with EGFR exon 19 deleted metastatic non-small cell lung cancer and asymptomatic brain metastases.

In this segment, the panel discusses how complex treatment education is operationalized in routine practice for patients with EGFR mutated metastatic non-small cell lung cancer.

In this segment, Dr. Devarakonda asks Dr. Rous to explore how treatment schedules and dosing flexibility influence shared decision making and long term adherence in EGFR mutated metastatic non-small cell lung cancer.

In this segment, the discussion centers on proactive toxicity management strategies in EGFR mutated metastatic non-small cell lung cancer.

In this segment, Dr. Devarakonda asks Dr. Rous to interpret the clinical implications of the FDA approval of subcutaneous amivantamab in combination with lazertinib, including the availability of once monthly dosing.

In this segment, Dr. Devarakonda asks Dr. Singhi to address how route of administration and treatment logistics influence clinical decision making in EGFR mutated metastatic non-small cell lung cancer.

In this segment, Dr. Devarakonda asks Dr. Rotow to move beyond clinical trial data and discuss the real world factors that influence first line treatment selection in EGFR mutated metastatic non-small cell lung cancer.

In this segment, Dr. Devarakonda asks Dr. Rotow to outline the advantages and limitations of combination regimens compared with single agent EGFR tyrosine kinase inhibitors in the first line treatment of EGFR mutated metastatic non-small cell lung cancer.

In this segment, Dr. Devarakonda invites the panel to reflect on how updated clinical guidelines are shaping first line treatment patterns in EGFR mutated metastatic non-small cell lung cancer.

Experts weigh EGFR lung cancer combo therapies, cautioning against cross-trial comparisons and prioritizing CNS efficacy for brain metastases.

Experts unpack new EGFR-mutant lung cancer first-line options, weighing survival, CNS control, and toxicity as combo regimens reshape practice.